Economic consequences and potential benefits

Nov 11, 2017 by in RHEUMATOLOGY Comments Off on Economic consequences and potential benefits

Abstract Patients with established rheumatoid arthritis (RA) may incur important resource utilisation and work productivity loss, resulting in high costs of illness. Impairment in physical function, which increases with disease…

read more

Anti-TNF therapy

Nov 11, 2017 by in RHEUMATOLOGY Comments Off on Anti-TNF therapy

There are now five anti-tumour necrosis factor (TNF) drugs licenced for use in rheumatoid arthritis. This chapter examines the similarities and differences between the drugs and looks for clues with…

read more

Imaging in rheumatoid arthritis

Nov 11, 2017 by in RHEUMATOLOGY Comments Off on Imaging in rheumatoid arthritis

The optimal management of rheumatoid arthritis (RA) requires tools that allow early and accurate disease diagnosis, prediction of poor prognosis and responsive monitoring of therapeutic outcomes. Conventional radiography has been…

read more

Established rheumatoid arthritis: Rationale for best practice – Physicians’ perspective of how to realise tight control in clinical practice

Nov 11, 2017 by in RHEUMATOLOGY Comments Off on Established rheumatoid arthritis: Rationale for best practice – Physicians’ perspective of how to realise tight control in clinical practice

Abstract Developments in the understanding of the pathogenesis of rheumatoid arthritis (RA) and the introduction of targeted biologic therapies have greatly advanced the management of RA in clinical practice. The…

read more

Co-morbidities in established rheumatoid arthritis

Nov 11, 2017 by in RHEUMATOLOGY Comments Off on Co-morbidities in established rheumatoid arthritis

Abstract Co-morbid conditions are common in patients with rheumatoid arthritis (RA). Although the presence of co-morbid conditions can be assessed using standardised indexes such as the Charlson index, most clinicians…

read more
Get Clinical Tree app for offline access